Longevity Health Q1 pro forma sales $663k, merger with 20/20 BioLabs progressing

Longevity Health Holdings, Inc.

XAGE Q1 unaudited pro forma sales ~$663k (+8% YoY); 20/20 sales ~$562k (+15% YoY).
Merger agreement with 20/20 signed April 11; S-4 filed May 8; closing subject to conditions.
1-for-30 reverse stock split completed May 12; trading at split-adjusted price from May 14.
Expected Q2 launches: XAGE medicated cleanser, 20/20 inflammatory biomarker test, and OneTest pilot with Giant Food.
Company evaluating options for additional financing, anticipates primary investment in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.